GlassScriptPhysician profile
Rebekah E Contini
NPI 1598026429
$1,804.32
in general payments reported to CMS, 2019-2025
25 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.73 · 2020: $11.07 · 2021: $334 · 2022: $310 · 2023: $464 · 2024: $357 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045 · Education: $85.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.88 |
| Education | $85.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $482.52 | 2021-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $183.89 | 2021-2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $174.73 | 2022-2024 | Veozah |
| Novo Nordisk INC | $119.75 | 2023-2025 | Wegovy, Ozempic |
| Phathom Pharmaceuticals, INC. | $118.36 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $104.14 | 2021-2025 | Farxiga |
| Lilly USA, LLC | $94.86 | 2021-2025 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $79.36 | 2021-2024 | |
| Nevro Corp. | $64.55 | 2023-2024 | Senza |
| Bayer Healthcare Pharmaceuticals INC. | $59.85 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $35.43 | 2021-2023 | Xarelto |
| Esperion Therapeutics, INC. | $31.65 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $30.35 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.42 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $25.94 | 2024 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $25.71 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $23.95 | 2025 | |
| Dexcom, INC. | $23.48 | 2021 | |
| Jazz Pharmaceuticals INC. | $21.82 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.19 | 2022 | |
| Exact Sciences Corporation | $13.90 | 2025 | Cologuard Collection Kit |
| Scynexis, INC. | $11.99 | 2022 | |
| Amgen INC. | $11.10 | 2021 | |
| Supernus Pharmaceuticals, INC. | $11.07 | 2020 | |
| Inogen, INC. | $7.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebekah Contini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.